Compare MINISO Group Holding Ltd (MNSO) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MINISO Group Holding Ltd vs 10X Genomics Inc — how do they compare? MINISO Group Holding Ltd trades at $9.13 (market cap $2.81B), while 10X Genomics Inc trades at $67.8 (market cap $8.55B). The key difference: 10X Genomics Inc is far larger — about 3× MINISO Group Holding Ltd's market cap, and MINISO Group Holding Ltd pays a 7.12% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| MNSO | TXG | |
|---|---|---|
Market Cap | $2.81B | $8.55B |
Sector | Technology | Health |
52-Week High | $25.31 | $67.29 |
52-Week Low | $9.23 | $11.34 |
Enterprise Value | $3.68B | $8.08B |
Dividend Yield | 7.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MNSO trades at $9.36, down 2.09% today, with mixed technical signals showing bearish moving averages but bullish oscillators including oversold RSI levels. Fundamentally, the company reported strong Q1 2026 earnings beat but missed expectations in three of the last four quarters. Revenue grew 22.4% YoY in H1 2026 to RMB 11.5 billion, driven by domestic China performance and store expansion, though overseas markets showed weakness. The company announced a HK$2 billion share repurchase program in June 2026 to support shareholder value.
The stock presents a value opportunity with attractive valuation multiples (P/E 15.25, P/S 0.82) below industry averages, supported by 60% analyst buy ratings and $11.05 consensus price target offering 18% upside. However, inconsistent earnings performance, competitive retail pressures, and overseas execution risks warrant caution. The oversold technical condition suggests potential near-term rebound potential if fundamental improvements materialize.
TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.
The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MINISO Group Holding Ltd
MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
